Background

All posts tagged Galway

Posted:
September 22, 2014
Tags:
Comments:
0
Human Bone Marrow MSCs

NUI Galway has signed an agreement to formalise collaborative ties with the Mayo Clinic Centre for Regenerative Medicine in the US. The agreement follows many years of close cooperation, and paves the way for joint collaborations in clinical trials using regenerative therapies.

(You can check out REMEDI’s research in an upcoming episode of Series 3 of The Science Squad, due for broadcast this Autumn on RTE One)

Collaborative research projects will focus on a number of key strategic areas of importance for both institutes, including adult stem cell therapy, gene therapy, biomaterials and biomedical engineering. Furthermore, the agreement facilitates ongoing student and staff exchange between Galway and the US.

The Memorandum of Understanding (MOU) puts the emphasis on regulatory science to facilitate global translation of regenerative medicine therapies to the clinic. Both the National University Ireland Galway and the Mayo Clinic Centre for Regenerative Medicine have GMP cell manufacturing facilities, licensed for use by the respective national medical authorities.

National University of Ireland Galway’s President, Dr Jim Browne, welcoming the signing of the MOU, said: “Formalising our longstanding links paves the way for advancing our common agenda which is to realize the potential of regenerative medicine. Here in Galway we have Ireland’s only facility licenced to produce stem cells for human use, while the new clinical and translational research facility for conducting clinical trials with patients will be complete in early 2015.”

NUI Galway’s Regenerative Medicine Institute (REMEDI) and the Network of Excellence for Functional Biomaterials (NFB), both of which are supported by Science Foundation Ireland, are working together specifically to develop joint clinical trial programmes in the area of regenerative medicine.

Professor Tony Windebank, Deputy Director for Discovery of the Centre for Regenerative Medicine at Mayo Clinic said: “Mayo Clinic and NUI Galway have an established track record and commitment to regenerative medicine over the last decade. The Mayo Clinic has prioritized the development of new regenerative medicine clinical applications as a critical strategy for meeting the needs of patients in the future, which was evidenced in the formation of our Centre for Regenerative Medicine in 2012.”

The signing of the MOU comes on top of the recent announcement of a new $16 million agreement between Mayo Clinic and Enterprise Ireland where up to 20 novel medical technologies will be commercialised in Ireland over the next five years with the aim of creating several high value medical technology spin-out companies.

Video featuring Professor Tony Windebank, Deputy Director for Discovery of the Centre for Regenerative Medicine at Mayo Clinic https://www.youtube.com/watch?v=B98ci3iAknE

Posted:
January 27, 2014
Tags:
Comments:
0
Neural Stem Cells
Stem cells can be manufactured for human use for the first time in Ireland, following Irish Medicines Board licensing of a new facility in Galway.

NUI Galway’s Centre for Cell Manufacturing Ireland aims to culture adult stem cells to tackle conditions such as arthritis, heart disease, diabetes and associated conditions.

The centre, which is one of less than half a dozen in Europe authorised for stem cell manufacture, has been developed by researchers at NUIG’s regenerative medicine institute.

Stem cells serve as the body’s repair mechanism. They can be isolated from tissues such as bone marrow and fat, and cultured in laboratory settings.

More controversially, embryonic stem cells have been highly valued for their ability to turn into any type of cell in the body, but scientists can now use reprogrammed adult skin cells to create a stem cell that is very similar to embryonic versions.

The centre will be opened today by Minister of State for Research and Innovation Seán Sherlock, at a time when the Health Research Board and Science Foundation Ireland have approved funding there for clinical trials on using mesenchymal stem cells – cells that can differentiate into a variety of types – for treatment of critical limb ischemia, a condition associated with diabetes that can result in amputation.

The new centre’s director Prof Tim O’Brien explained that the stem cells must be grown in the laboratory to generate sufficient quantities, following their isolation from the bone marrow of adult donors, and the facility will help Ireland to develop therapies for a broad range of clinical problems which do not have effective treatments today.

“It will also allow us to translate discoveries from the basic stem cell research programme led by Prof Frank Barry at the Science Foundation Ireland-funded REMEDI to the clinic, and to be competitive for grant funding under the Horizon 2020 programme of the EU,” he said.

Stem cell research in Ireland is in what scientists have described as a “legislative lacuna”, but this relates to use of embryonic stem cells and does not in any way inhibit the use of adult stem cells, Prof O’Brien explained.

“We can only engage in clinical trials with clinical authorisation from the IMB and approval from the hospital ethics committee, and we are currently seeking such approval for clinical trials,”he said.

“The license to manufacture is an essential pre requisite to seek permission to undertake clinical trials. The license certificate must be included with the clinical trial authorisation application.”

NUIG president Dr Jim Browne said the centre develops Galway’s role as a “med tech hub of global standing”, while Irish Medical Devices Association board member John O’Dea has pointed to the lucrative revenue to be earned from regenerative medicine products, valued at about €1.3 billion in 2013 and with a 40 per cent sales growth last year.

Some 70 per cent of pharmaceutical companies are working on regenerative medicine therapies – an area described as a crossover between biology and engineering – and NUIG estimates that there are over 1,900 cell therapy clinical trials under way globally.

(Report taken from the Irish Times)

Posted:
November 14, 2013
Tags:
Comments:
0
reellife-science-image-1

The winners of the inaugural ReelLife Science Science Communication video competition for primary and secondary schools were announced this week.

First place in the Secondary Schools competition went to “Life in Space” (click here to view video) created by St. Enda’s College Transition Year student Michael McAndrew, under the direction of Mr. Fahey and Mr. Conroy. The short film combines a fantastic concept and animation style with an intelligent script, wonderful delivery and original score. The film describes the fascinating field of Astrobiology, encompassing the origin and future of life on earth and the search for extraterrestrial life in other “Goldilocks Zones”. In Michael’s own words “it is very exciting what the future might bring us“.

In the Primary Schools competition, first place went to a video as Gaeilge about Seed Dispersal called “Scaipeadh siolta i Rosmuc” (click here to view video). This memorable video was made by the 5th and 6th class students in Scoil Mhuire Rosmuc, under the direction of their teacher Ms. Ni Chonaola. The students took a very specific topic in Seed Dispersal and Germination, and produced three very amusing and informative sketches demonstrating different methods of dispersal. Furthermore, they performed some experiments of their own on the various seeds they found, identifying the different traits associated with them, based on their method of dispersal.

The winners (and the second and third runners up) will be invited to attend the Galway Science and Technology Festival at the end of November in NUI Galway, to receive their prizes and certificates, and to see the shortlisted videos on display to the general public.

To view the videos and for further information about the ReelLife Science project click here